Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;74(1):79-89.
doi: 10.1007/s00228-017-2344-x. Epub 2017 Oct 3.

Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation

Affiliations

Population pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation

Dorota Danielak et al. Eur J Clin Pharmacol. 2018 Jan.

Abstract

Purpose: There is an increasing interest in use of treosulfan (TREO), a structural analogue of busulfan, as an agent in conditioning regimens prior to hematopoietic stem cell transplantation (HSCT), both in pediatric and adult populations. The aim of this study was to develop a population pharmacokinetic model and to establish limited sampling strategies (LSSs) enabling accurate estimation of exposure to this drug.

Methods: The study included 15 pediatric patients with malignant and non-malignant diseases, undergoing conditioning regimens prior to HSCT including TREO administered as a 1 h or 2 h infusion at daily doses of 10, 12, or 14 g/m2. A population pharmacokinetic model was developed by means of non-linear mixed-effect modeling approach in Monolix® software. Multivariate regression analysis and Bayesian method were used to develop 2- and 3-point strategies for estimation of exposure to TREO.

Results: Pharmacokinetics of TREO was best described with a two-compartmental linear model with proportional residual error. Following sampling schedules allowed accurate estimation of exposure to TREO: 1 h and 6 h or 1 h, 2 h, and 6 h for a TREO dose 12 g/m2 in a 1 h infusion, or at 2 h and 6 h or 2 h, 4 h, and 8 h for a TREO dose of 12 g/m2 and 14 g/m2 in a 2 h infusion.

Conclusions: A two-compartmental population pharmacokinetic model of TREO was developed and successfully used to establish 2- and 3-point LSSs for accurate and precise estimation of TREO AUC0→∞.

Keywords: Area under curve; Hematopoietic stem cell transplantation; Infusions, intravenous; Population pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

Ethical approval

All procedures performed in study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Contributions of authors

D. Danielak supervised the study, performed modeling, validation, sampling strategy development and wrote the manuscript. J. Twardosz performed modeling and validation procedures. A. Kasprzyk developed the HPLC-MS/MS method and determined treosulfan concentrations. J. Wachowiak and K. Kałwak supervised patient recruitment and critically reviewed the manuscript. F. Główka supervised the study and critically reviewed the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Metabolic activation of treosulfan to its active mono- and diepoxide
Fig. 2
Fig. 2
Spaghetti plot of treosulfan concentrations vs. time acquired for patients included in the study
Fig. 3
Fig. 3
Goodness-of-fit plots for the final pharmacokinetic model. Panel A illustrates observed (OBS) vs. population predicted (PPRED) treosulfan concentrations and OBS vs. individual predicted (IPRED) treosulfan concentrations with an identity line and smooth. Panel B presents individual-weighted residuals (IWRES) vs. time and PPRED, population-weighted residuals (PWRES) vs. time and PPRED. Panel C presents normalized prediction distribution errors (NPDE) vs. time and PPRED with bold lines as 5th, median and 95th percentile of observed concentrations, light gray area as 50% interval of simulated data and dark gray areas as 95% intervals of simulated data
Fig. 4
Fig. 4
Prediction-corrected visual predictive check (pcVPC) with dots as observed treosulfan concentrations, bold lines as 5th, median and 95th percentile of observed concentrations, light gray area as 50% interval of simulated data and dark gray areas as 95% intervals of simulated data

Similar articles

Cited by

References

    1. Ljungman P, Bregni M, Brune M, Cornelissen J, de WT, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2009;45:219–234. doi: 10.1038/bmt.2009.141. - DOI - PubMed
    1. Główka FK, Romański M, Wachowiak J. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert Opin Investig Drugs. 2010;19:1275–1295. doi: 10.1517/13543784.2010.517744. - DOI - PubMed
    1. Wachowiak J, Sykora KW, Cornish J, Chybicka A, Kowalczyk JR, Gorczynska E, Choma M, Grund G, Peters C. Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT Pediatric Diseases Working Party. Bone Marrow Transplant. 2011;46:1510–1518. doi: 10.1038/bmt.2010.343. - DOI - PubMed
    1. Slatter MA, Boztug H, Pötschger U, Sykora K-W, Lankester A, Yaniv I, Sedlacek P, Glogova E, Veys P, Gennery AR, Peters C, Inborn Errors EBMT, Parties PDW. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50:1536–1541. doi: 10.1038/bmt.2015.171. - DOI - PubMed
    1. Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins A-M, Gibson B, Sedlacek P, Krol L, Strahm B, Zaidman I, Kalwak K, Talano J-A, Woolfrey A, Fraser C, Meyts I, Müller I, Wachowiak J, Bernardo ME, Veys P, Sykora K-W, Gennery AR, Slatter M. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128:440–448. doi: 10.1182/blood-2016-03-704015. - DOI - PMC - PubMed

MeSH terms